EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dupilumab for the Treatment of Eosinophilic Esophagitis: Real‐Life Long‐Term Effectiveness, Safety and Retreatment After Drug Holiday

Elisabetta Favero, Vera Bonato, Michele Campigotto, Ilaria Bertozzi, Patrick Bez, Veronica Vanin, Marta Ascolani, Antonino Caruso, Luisa Bertin, Edoardo Vincenzo Savarino, Valentina Angerilli, Matteo Fassan und 3 weitere

JGH Open · 2026-11 · 10 (11)

DOI: 10.1002/jgh3.70504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JGH Open, online erschienen am 16.11.2026. Verfasst von Elisabetta Favero und 14 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Eosinophilic esophagitis (EoE) is a chronic T‐helper Type 2 (Th2)‐mediated inflammatory disorder with sharply increasing incidence and prevalence. While dupilumab is the first biologic approved for EoE, long‐term real‐world data on effectiveness, safety, and treatment discontinuation outcomes remain scarce.

Methods

We conducted a prospective single‐center observational study of adult patients with EoE treated with dupilumab. Clinical, endoscopic, and histological effectiveness, safety profile, and outcomes following accidental treatment discontinuation were analyzed.

Results

Ten patients were included with a median follow‐up of 57 months (IQR 44.25–64.75). The median SDI‐PRO score decreased from 1 (IQR 0–3.75) to 0 (IQR 0–0) points at 6 months and remained 0 (IQR 0–0) points at last follow‐up. Endoscopic and histological remission were achieved in most patients after 6 months of therapy (100% and 70%, respectively) and at last follow‐up (100% and 100%, respectively). No serious adverse events were observed. Notably, two patients who accidentally discontinued therapy experienced rapid clinical and endoscopic relapse within a few weeks and regained complete remission within 1 month of retreatment.

Conclusions

This study provides long‐term real‐world data supporting the sustained effectiveness and favorable safety profile of dupilumab in EoE. The rapid relapse observed after accidental discontinuation, even in patients with deep remission, highlights the importance of identifying predictors of relapse before considering dose de‐escalation strategies.

Zitieren

APA

Favero, E., Bonato, V., Campigotto, M., Bertozzi, I., Bez, P., Vanin, V., Ascolani, M., Caruso, A., Bertin, L., Savarino, E. V., Angerilli, V., Fassan, M., Rattazzi, M., Cinetto, F., & Felice, C. (2026). Dupilumab for the Treatment of Eosinophilic Esophagitis: Real‐Life Long‐Term Effectiveness, Safety and Retreatment After Drug Holiday. JGH Open, 10(11). https://doi.org/10.1002/jgh3.70504

Vancouver

Favero E, Bonato V, Campigotto M, Bertozzi I, Bez P, Vanin V, et al. Dupilumab for the Treatment of Eosinophilic Esophagitis: Real‐Life Long‐Term Effectiveness, Safety and Retreatment After Drug Holiday. JGH Open. 2026;10(11). doi:10.1002/jgh3.70504

BibTeX
@article{Favero2026,
  author = {Favero, Elisabetta and Bonato, Vera and Campigotto, Michele and Bertozzi, Ilaria and Bez, Patrick and Vanin, Veronica and Ascolani, Marta and Caruso, Antonino and Bertin, Luisa and Savarino, Edoardo Vincenzo and Angerilli, Valentina and Fassan, Matteo and Rattazzi, Marcello and Cinetto, Francesco and Felice, Carla},
  title = {Dupilumab for the Treatment of Eosinophilic Esophagitis: Real‐Life Long‐Term Effectiveness, Safety and Retreatment After Drug Holiday},
  journal = {JGH Open},
  year = {2026},
  volume = {10},
  number = {11},
  doi = {10.1002/jgh3.70504}
}
Kostenlos starten →